Highlights

  • TLX shares closed at $16.16, up 3.46% on 24 August 2026
  • FY2026 half-year group Revenue reached US$477 million, up 22% year-on-year
  • Gross Margin increased to 55%, with Precision Medicine gross margin reaching 65%
  • Full-year revenue guidance maintained at US$950 million-US$970 million

Telix Pharmaceuticals Ltd (ASX:TLX) shares closed at $16.16, up 3.46% on 24 August 2026. The stock has become an increasingly popular talking point among investors weighing exposure to the radiopharmaceutical sector, supported by the company's commercial momentum and expanding product portfolio.

About Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Ltd is a biopharmaceutical company focused on the development and commercialisation of radiopharmaceutical products used in the diagnosis and treatment of cancer and other serious diseases. The company's core Business spans both diagnostic imaging agents and therapeutic radiopharmaceuticals, with its Precision Medicine division representing an increasingly important contributor to overall revenue and profitability. Telix has built a commercial presence across key global markets, supporting the sale of its approved products while simultaneously advancing a late-stage pipeline of additional radiopharmaceutical candidates targeting various cancer types. This combination of an established commercial business and an active pipeline provides Telix with both near-term revenue generation and longer-term growth optionality as new products progress through clinical development and toward potential regulatory approval. As the radiopharmaceutical sector continues to attract growing interest from clinicians and healthcare systems for its precision-targeting capabilities in oncology, Telix has positioned itself as one of the more advanced companies in this specialised and rapidly evolving field.

Key Developments

Telix delivered strong FY2026 half-year results, reporting US$477 million in group revenue, up 22% year-on-year, a result that highlights the continued commercial momentum behind the company's approved radiopharmaceutical products. Gross margin increased to 55%, while Precision Medicine gross margin reached 65%, reflecting favourable product mix and ongoing operational efficiencies within the business. These margin improvements are particularly notable as they suggest Telix is not only growing revenue but doing so with increasing profitability, a key consideration for a company at this stage of commercial scale-up. Management maintained full-year revenue guidance of US$950 million to US$970 million, demonstrating continued confidence in the company's commercial trajectory and providing investors with a clear benchmark for assessing performance over the remainder of the financial year. Telix is also progressing its late-stage pipeline of radiopharmaceutical products, an important complement to its current commercial success, and plans to hold an R&D Day in New York on 22 September, an event that should provide further detail on the company's pipeline progress and longer-term growth strategy. The combination of strong commercial growth and continued pipeline development remains central to Telix's overall Investment story.

Conclusion

Telix Pharmaceuticals's strong half-year results, marked by 22% revenue growth and improving margins, underscore the continued commercial success of its radiopharmaceutical portfolio. With full-year guidance maintained and an upcoming R&D Day set to shed further light on the company's pipeline, Telix appears well positioned to sustain its growth trajectory. Investors will be watching closely for further updates on pipeline progress and commercial execution as the company works toward its full-year targets.